FOCUS-Europe ready to cash in on cheap copies of AbbVie biotech drug


U.S. drugmaker AbbVie ABBV.N faces a crunch moment in Europe in mid-October when less-expensive copies of its $18-billion-a-year biologic drug Humira - the world's best-selling prescription medicine - hit the market. A screen displays the share price for pharmaceutical maker AbbVie on the floor of the New York Stock Exchange July 18, 2014.



from Biotech News